Journal profile · Neurosciences
Journal of Neuroimmune Pharmacology
ISSN 1557-1890 · eISSN 1557-1904 · Springer US · UNITED STATES · Quarterly · Founded 2006
Journal of Neuroimmune Pharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.22; hybrid open access; APC about USD 4,790; median 172 days to acceptance (93 articles, last 24 months); 106 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Neuroimmune Pharmacology is published by Springer US and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neuroinflammation and Neurodegeneration Mechanisms, HIV Research and Treatment and Tryptophan and brain disorders, together about 45.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The aims of the Journal of Neuroimmune Pharmacology are to promote the dissemination, interest, and exchange of new and important discoveries for the pharmacology and immunology of the nervous system. Through its publications, the Journal seeks to increase the fundamental understanding of neurologic and neuropsychiatric disorders affected by the immune system or vice versa and towards pharmacologic measures that lead, either to a better understanding of disease mechanisms, or by improving disease outcomes. The scope of JNIP includes all primary works and reviews into the etiology, prevention, and treatment of neuroimmune and nervous system diseases affected by disordered immunity. Original studies serving to define neuroimmune modulation of environmental or endogenous cues such as toxins and drugs of abuse, hormones, and cytokines are welcome. JNIP will serve as a reliable source of interdisciplinary information bridging the fields of pharmacology, immunology, and neuroscience.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief Jay RappaportPublisher website
Editorial board by country: none in mainland China; most named United States 17, United Kingdom 1, Jordan 1 (19 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience21.1%
- HIV Research and TreatmentImmunology and Microbiology14.7%
- Tryptophan and brain disordersNeuroscience9.5%
- Alzheimer's disease research and treatmentsMedicine5%
- Cannabis and Cannabinoid ResearchMedicine4.2%
- Neuroscience and Neuropharmacology ResearchNeuroscience3.8%
- Multiple Sclerosis Research StudiesMedicine3%
- Immune Cell Function and InteractionImmunology and Microbiology3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Neurosciences | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Neurosciences | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Neurosciences | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, AGRICOLA, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.22LetPub ·
- Impact factor (publisher) 2025
- 6.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.7Publisher website ·
- CiteScore 2026-06
- 6.4LetPub ·
- SJR 2026-06
- 1.46LetPub ·
- SNIP 2026-06
- 0.98LetPub ·
- h-index
- 64LetPub ·
- h-index
- 109OpenAlex ·
- i10-index
- 921OpenAlex ·
- 2-year mean citedness
- 6.11OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 37.37%LetPub ·
Volume
- Articles per year
- 103LetPub ·
- Downloads per year (publisher) 2025
- 548,700Publisher website ·
Articles by year OpenAlex count · 1,311 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 50 | 14 | 23 |
| 2025 | 106 | 45 | 544 |
| 2024 | 61 | 22 | 759 |
| 2023 | 39 | 19 | 654 |
| 2022 | 18 | 9 | 263 |
| 2021 | 67 | 51 | 1,849 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
172 daysMedian, submission to acceptance · P25–P75 127 days – 244 days
- Acceptance to online
- median 21 days (93 articles)
- Submission to online
- median 199 days
- Sample
- 93 articles with submission and acceptance dates (168 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Submission to first decision
- 26 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,790 / EUR 3,690 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Author–date
- Suggested reviewers
- Optional
- Graphical abstract
- Required
Article types accepted6, with length limits
- brief reportOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…Length not stated
- commentaryOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…Length not stated
- letters to the editorOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…main text ≤ 1,000 words
- original articleOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…Length not stated
- perspectiveOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…Length not stated
- reviewOriginal Article: No page limitations but usual length is 20-30 pages (double spaced) with up to 60 references and 8 figures plus tables Reviews: 20-30 pages, d…main text ≤ 7,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship AUTHORSHIP CRITERIA AND CONTRIBUTION
The International Committee of Medical Journal Editors has recommended the following criteria for authorship Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be publis…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
Research data archiving encouraged Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
COPE member Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Journal of Neuroimmune Pharmacology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2006
- ISSN
- 1557-1890
- Electronic ISSN
- 1557-1904
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
FAQ
Frequently asked questions about Journal of Neuroimmune Pharmacology
What CAS zone is Journal of Neuroimmune Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Neuroimmune Pharmacology is in Zone 3 of Medicine, and in Zone 3 of the minor category Neurosciences / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Neuroimmune Pharmacology?
The latest impact factor listed by LetPub is 6.22; CiteScore 6.4, h-index 109.
How long does peer review take at Journal of Neuroimmune Pharmacology?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 172 days (interquartile range 127–244 days); authors report an average review time of 6–12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Neuroimmune Pharmacology?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Author–date; Suggested reviewers: Optional; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Neuroimmune Pharmacology based?
Of the 19 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (17), United Kingdom (1) and Jordan (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Neuroimmune Pharmacology?
According to LetPub and DOAJ records, Journal of Neuroimmune Pharmacology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE and Embase; that list has not been checked against each database.
Is Journal of Neuroimmune Pharmacology open access, and what is the APC?
Journal of Neuroimmune Pharmacology is a hybrid journal. For open-access publication: APC about USD 4,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .